Navigation Links
ENDECE Neural to Present Findings at 2013 Biotech Showcase on NDC-1308 which Induces Remyelination of Demyelinated Axons
Date:12/10/2012

MEQUON, Wis., Dec. 10, 2012 /PRNewswire/ -- ENDECE Neural, LLC (www.endeceneural.com) announced today that the company will be presenting at the 2013 Biotech Showcase in San Francisco, California, January 8th.

The ENDECE Neural presentation, to be given by Dr. James Yarger, CEO, will discuss the company's novel therapeutic for directly inducing remyelination of demyelinated axons to treat neurological diseases such as Multiple Sclerosis (MS).

Currently there are no drugs commercially available for remyelination in MS, or any other disease associated with demyelination. ENDECE Neural may have one of the first compounds with the ability to directly induce remyelination.

"This novel therapeutic could be used either alone or in combination with current immunosuppressant/anti-inflammation therapies," says Dr. Yarger. "We are looking to partner with or license this exciting opportunity to potentially restore function, mobility and independence to those fighting MS." 

About ENDECE Neural, LLC (an ENDECE Company)
ENDECE Neural is the wholly owned subsidiary of ENDECE, LLC. ENDECE Neural was founded in 2011 to focus on the development of what could be the first drug capable of inducing remyelination of damaged nerve axons, and potentially restoring muscle control, mobility and independence to the lives of Multiple Sclerosis patients. ENDECE Neural maintains an exclusive license for the IP from its parent company.

About Biotech Showcase (Innovation – Opportunity – Collaboration)
Now in its fifth year, Biotech Showcase (www.ebdgroup.com/bts) features corporate presentations by 195 innovative life science companies to public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®. Public and private investors are always invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry.


'/>"/>
SOURCE ENDECE Neural, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. First Neurally Controlled, Powered Prosthetic Limb Is 2,109 Steps Closer To Realization
2. Neural implant recovers ability to make decisions
3. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
4. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
5. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
6. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
7. Triangles guide the way for live neural circuits in a dish
8. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
9. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
10. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
11. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems everyone ... and culture intertwine to create an expressive and dynamic community ... this energy and contribute to it. With ... Hair Fairies seeks to carry on that tradition with ... Atlanta salon is the newest of 13 ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... (such as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs ... Insulin Assay from Salimetrics’ SalivaLab , the relationship between insulin and other ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... research tools, announced the acquisition of GenWay Biotech ... a comprehensive service and product offering for both ... acquisition will facilitate growth and enhance capabilities for ... antibodies, and ELISA assays will nicely complement ASB,s ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
Breaking Biology News(10 mins):